Summary
MetLife, Inc. (MET) filed an 8-K on May 17, 2021, primarily announcing two significant corporate actions related to its preferred stock. First, the company declared quarterly dividends for several series of its preferred stock, including Series A, Series C, Series E, and Series F. This indicates continued regular payouts to preferred shareholders. More notably, MetLife announced its intention to redeem all outstanding shares of its Series C Preferred Stock on June 15, 2021. The redemption will occur at the liquidation preference of $1,000 per share. This action suggests a strategic financial move by MetLife, potentially to streamline its capital structure or reduce interest expenses associated with this series of preferred stock.
Key Highlights
- 1Declaration of quarterly dividends for MetLife's Series A, C, E, and F preferred stocks.
- 2MetLife to redeem all outstanding Series C Preferred Stock.
- 3Redemption date for Series C Preferred Stock set for June 15, 2021.
- 4Redemption price for Series C Preferred Stock is $1,000 per share.
- 5The redemption of Series C Preferred Stock will not include any accrued and unpaid dividends.
- 6The filing includes news releases as exhibits detailing the dividend declarations and the Series C redemption.
- 7This 8-K filing focuses on routine dividend announcements and a specific capital management action (redemption).
Frequently Asked Questions
The main purpose of this 8-K filing is to officially announce the declaration of quarterly dividends for several series of MetLife's preferred stock and to announce the upcoming redemption of all outstanding shares of its Series C Preferred Stock.
The Series C Preferred Stock will be redeemed on June 15, 2021, at a price of $1,000 per share.
No, the redemption of the Series C Preferred Stock at $1,000 per share will not include any accrued and unpaid dividends.
This filing exclusively details dividend declarations for preferred stock (Series A, C, E, and F) and the redemption of Series C Preferred Stock. It does not mention dividends for MetLife's common stock.